



CLINICAL RESEARCH PROTOCOLS FOR THYROID CANCER

*This list of clinical
research protocols
relating to thyroid
cancer is compiled
for your convenience.*

CMMI-C-040A-98, NCI-V99-1564, CMMI-FDR001555 Phase I/II Study of Radioimmunotherapy with Yttrium Y 90 Anti-CEA Monoclonal Antibody MN-14 With or Without Doxorubicin Plus Peripheral Blood Stem Cell Rescue in Patients With Medullary Thyroid Carcinoma

Chairperson: Malik Juweid.
Telephone: 973-844-7115. Lead organization: Garden State Cancer Center. Age range: 16 to 80.

CAN-OTT-9401, NCI-V94-0566, CLB-9871 Phase II Study of Cisplatin/Doxorubicin/Tamoxifen for Incurable Soft Tissue and Endocrine Malignancies

Chairperson: Stan Z. Gertler.
Telephone: 613-737-7700. Lead organization: Ottawa Regional Cancer Centre - Civic Campus. Age range: 65 and under.

Legend for Abbreviations:

- CAN-OTT = Ottawa Regional Cancer Centre
- CLB = Cancer & Leukemia Group B
- CMMI = Center for Molecular Medicine & Immunology
- NCI = National Cancer Institute

For more information on these protocols, please call PDQ, a service of the National Cancer Institute, at 1-800-4-CANCER.

A searchable PDQ Web site is also accessible at <http://cancernet.nci.nih.gov/trialsrch.shtml>